OMG! Cream for Female Arousal
All participants had a main diagnosis of FSAD and may have also had concomitant sexual dysfunction diagnoses or symptoms including decreased desire, orgasmic dysfunction, and genital pain. Exploratory Phase 2b clinical study designed to evaluate Sildenafil Cream vs. placebo over 12 weeks of double-blinded dosing following both a non-drug and placebo run-in period: Compared Sildenafil Cream vs. placebo used in patients’ home setting.
Up to 40% of women report low sexual desire or interest, and women are 2-3x more likely than men to experience a decline in sex drive as they age
DARE to PLAY™ is the first and only topical formulation of sildenafil developed specifically for women and backed by: Toxicology studies covering oral, anal, vaginal, and reproductive health; Multiple clinical trials in women, including a randomized placebo-controlled study with 200 women and their sexual partners; and Published, peer-reviewed research in medical journals such as The Green Journal, the official publication of the American College of Obstetrics and Gynecology (ACOG) and the Journal of Sexual Medicine, the official publication of the International Society for the Study of Women’s Sexual Health (ISSWSH). “As more women speak openly about their sexual health, the need for research-backed solutions has never been greater,” said Dr. Irwin Goldstein, Director of San Diego Sexual Medicine and a founder of ISSWSH. “Daré’s commitment to both clinical integrity and timely access ensures women who need it don’t have to wait to benefit from this innovation.” While continuing activities necessary to seek U.S. Food and Drug Administration (FDA) approval of its proprietary sildenafil cream formulation in the future, Daré Bioscience is making DARE to PLAY™ available as a Section 503B compounded product, manufactured in an outsourcing facility subject to FDA inspection and under current Good Manufacturing Practice (cGMP) regulations to ensure quality, strength and consistency.
Increased sexual response in a cream
Compounded drug products are not FDA approved. The FDA does not evaluate compounded drug products for safety, effectiveness, or quality. DARE to PLAY™ can now be prescribed for pre-order by licensed healthcare providers for prescription fulfillment in these states: CT, FL, IN, MO, NH, NJ, OR, PA, RI, and UT, and will ship within 45 days of order placement during the pre-order phase. DARE to PLAY™ prescriptions are being accepted through the DARE Health Hub, managed by Medvantx. DARE to PLAY™ will be available in other states throughout December and early 2026. Co-primary endpoints: patient reported outcome (PRO) instruments measured improvement in localized genital sensations of arousal (Arousal-Sensation Domain of the Sexual Function Questionnaire) and reduction in FSAD related distress (Female Sexual Distress Scale).
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 150mg | 180 + 10 Pills | 236.46€ 225.20€ | |
| Viagra Super Active | 100mg | 270 + 30 Pills | 390.61€ 372.01€ | |
| Viagra Generic | 25mg | 20 Pills | 37.74€ 35.94€ | |
| Viagra Generic | 100mg | 30 + 4 Pills | 60.91€ 58.01€ | |
| Viagra Generic | 25mg | 60 + 4 Pills | 71.99€ 68.56€ | |
| Viagra Generic | 50mg | 30 + 4 Pills | 54.26€ 51.68€ | |
| Viagra Professional | 100mg | 180 + 4 Pills | 337.30€ 321.24€ | |
| Viagra Generic | 150mg | 360 + 10 Pills | 423.48€ 403.31€ | |
| Viagra Generic | 150mg | 120 + 8 Pills | 177.58€ 169.12€ | |
| Viagra Oral Jelly | 100mg | 10 Sachets | 46.36€ 44.15€ | |
| Viagra Generic | 25mg | 360 + 10 Pills | 213.68€ 203.50€ | |
| Viagra Generic | 50mg | 120 + 6 Pills | 129.64€ 123.47€ |
Secondary endpoint: measured change in the number of satisfactory sexual events Exploratory endpoints: Several efficacy endpoints measured and could be candidate endpoints in a Phase 3 study. Efficacy assessments were administered both on an electronic diary to be completed within 24 hours of a sexual event and via 28-day recall assessments.
LinkOut - more resources
Regulatory Strategy for Sildenafil Cream, 3.6%: Next Steps The Company is working to align with the FDA on the Phase 3 study design. At the conclusion of the development program, if successful, Daré intends to leverage the existing safety and efficacy data for sildenafil to utilize the FDA’s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream, 3.6% for the treatment of women in the U.S. DOI: 10.1016/j.sxmr.2016.03.002 Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. Based on US Census projections for 2016. Dare Bioscience developed Dare to Play, a cream boosting female sexual arousal in 10 minutes The cream contains sildenafil, the active ingredient in Viagra, increasing vaginal blood flow Clinical trials showed Dare to Play improved libido and orgasms with no side effects versus placebo Over three decades after the invention of Viagra, a little blue pill that allows men to boost their sexual performance, scientists have developed a similar alternative for women.
Wisp Company Reviews
US-based health biotech group Dare Bioscience has created a $10 a use product that works in just 10 minutes and boosts women's arousal. The first-of-its-kind cream called "Dare to Play" contains sildenafil, the same active ingredient in Viagra. The topical treatment works by increasing blood flow in the vagina, improving sensation and arousal. “We have this scientific evidence that sildenafil as an active ingredient can work if only it were designed and formulated specifically with women in mind and that's really where we came into the equation," Sabrina Martucci Johnson, president and CEO of Dare Bioscience was quoted as saying by New York Post. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades." The Southern California company stated that it was continuing to seek necessary approvals for the product from the US Food and Drug Administration (FDA), adding that its effectiveness was backed by toxicology studies, multiple clinical trials and peer-reviewed research. Sildenafil Cream-treated group showed meaningful improvement in the co‑primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire, although the endpoint did not achieve statistical significance.1 Post-hoc analyses showed that Sildenafil Cream met the Ph2b co-primary endpoint (SFQ28-arousal domain patient reported outcome (PRO)) and demonstrated clinically meaningful benefit in patients who have FSAD or FSAD with concomitant decreased desire. Secondary and exploratory endpoints saw these patients report meaningful improvement in arousal sensation, desire, orgasm, as well as stress, guilt, and embarrassment about the sexual dysfunction. Read more about the Phase 2b clinical study here. Regulatory Strategy for Sildenafil Cream, 3.6%: Next Steps The Company is working to align with the FDA on the Phase 3 study design. At the conclusion of the development program, if successful, Daré intends to leverage the existing safety and efficacy data for sildenafil to utilize the FDA’s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream, 3.6% for the treatment of women in the U.S. DOI: 10.1016/j.sxmr.2016.03.002 Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. Based on US Census projections for 2016. Dare Bioscience developed Dare to Play, a cream boosting female sexual arousal in 10 minutes The cream contains sildenafil, the active ingredient in Viagra, increasing vaginal blood flow Clinical trials showed Dare to Play improved libido and orgasms with no side effects versus placebo Over three decades after the invention of Viagra, a little blue pill that allows men to boost their sexual performance, scientists have developed a similar alternative for women. US-based health biotech group Dare Bioscience has created a $10 a use product that works in just 10 minutes and boosts women's arousal.
- Viagra cream is part of a broader category of topical ED treatments.
- It offers an alternative for men who dislike oral medications.
- The product may be flavored or designed to mask medicinal taste.
- It can be used with other sexual enhancement products cautiously.
- Some users prefer creams for their discreet nature.
- Clinical research is ongoing into topical PDE5 inhibitors.
- Side effects may include skin rash or allergic reaction.
- Realistic expectations are important for satisfaction.
- Price varies based on brand, formulation, and availability.
- Always purchase from reputable sources to ensure quality.
The first-of-its-kind cream called "Dare to Play" contains sildenafil, the same active ingredient in Viagra. The topical treatment works by increasing blood flow in the vagina, improving sensation and arousal. “We have this scientific evidence that sildenafil as an active ingredient can work if only it were designed and formulated specifically with women in mind and that's really where we came into the equation," Sabrina Martucci Johnson, president and CEO of Dare Bioscience was quoted as saying by New York Post. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades." The Southern California company stated that it was continuing to seek necessary approvals for the product from the US Food and Drug Administration (FDA), adding that its effectiveness was backed by toxicology studies, multiple clinical trials and peer-reviewed research. During the trials, the Dare to Play cream increased libido as well as orgasms with no potential side effects compared to a placebo cream. It was also tested in oral sex situations.
| Step | Action | Details | Tips |
|---|---|---|---|
| 1 | Clean the skin surface | Use mild soap and water | Dry thoroughly before application |
| 2 | Apply a thin layer | Use a pea-sized amount | Avoid excess use |
| 3 | Massage gently into skin | Ensure even distribution | Wait 10 minutes before activity |
| 4 | Wash hands afterward | To prevent accidental transfer | Use gloves if sensitive skin |
"Phase 2b trial included 200 premenopausal women experiencing symptoms of female sexual interest/arousal disorder, such as reduced genital sensation and frustration during intimacy," the company said. After 12 weeks, women who used the cream reported an increase in arousal as well as key areas of sexual function, including desire and orgasm. Johnson said the new cream represents a "long overdue correction" that allows women an option to reconnect with their own bodies, with science finally recognising their needs as well. As for why a pill akin to those used by men was not developed, Johnson said a female pill would require a lot of sildenafil. She added that the option generic viagra sildenafil citrate 50 mg was "just not practical" as it would require much higher doses than what men generally need. Residents of Connecticut, Florida, Indiana, Missouri, New Hampshire, New Jersey, Oregon, Pennsylvania, Rhode Island and Utah can pre-order the cream already.
| Medication Type | Interaction Effect | Advice |
|---|---|---|
| Nitrates | Severe hypotension (low blood pressure) | Avoid concurrent use |
| Alpha-blockers | Enhanced blood pressure-lowering effect | Monitor blood pressure |
| CYP3A4 Inhibitors | Increased plasma levels of sildenafil | Dose adjustment needed |
Track Latest News Live on NDTV.com and get news updates from India and around the world Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal sensations based on clinically-validated endpoints.
| Form | Average Price | Dosage per unit | Advantages | Disadvantages |
|---|---|---|---|---|
| Cream | $25 per tube | 2.5g | Localized effect, quick onset | May cause skin irritation |
| Tablet | $20 per pill | 50mg | Easy to dose, well-studied | Systemic effects, longer onset |
| Injectable | $50 per injection | Variable | Rapid effect | Invasive, requires health professional |
Market introduction of DARE to PLAY™ is expected to mark a breakthrough in women’s sexual health and represents important progress toward closing one of medicine’s most persistent gender gaps.
How DARE to PLAY Sildenafil Cream Works
SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that providers in select states can now begin prescribing DARE to PLAY™ Sildenafil Cream, a proprietary topical arousal cream designed specifically for women to enhance genital blood flow and arousal response. DARE to PLAY™ represents the first and only evidence-backed sildenafil cream formulation for women. Its commercial availability through a 503B outsourcing facility will mark the first time a topical sildenafil formulation manufactured in accordance with cGMP requirements and supported by clinical data will be accessible to women.
Sildenafil in O-mazing
DARE to PLAY™ uses sildenafil, the same active ingredient found in Viagra®, to improve genital blood flow. Applied topically, it’s designed for use as needed, to enhance the body’s natural arousal response without systemic effects, providing women with a new, evidence-based tool to take charge of their sexual health. “When Viagra was approved in 1998, it revolutionized sexual medicine for men. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “We believe DARE to PLAY™ represents a long overdue correction, giving women an option to reconnect with their own bodies, their pleasure, and their confidence, using science that finally recognizes their needs.” Existing products promoted for arousal lean heavily on marketing language, consumer reviews, and lifestyle branding without real evidence. SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that providers in select states can now begin prescribing DARE to PLAY™ Sildenafil Cream, a proprietary topical arousal cream designed specifically for women to enhance genital blood flow and arousal response. DARE to PLAY™ represents the first and only evidence-backed sildenafil cream formulation for women. Its commercial availability through a 503B outsourcing facility will mark the first time a topical sildenafil formulation manufactured in accordance with cGMP requirements and supported by clinical data will be accessible to women. DARE to PLAY™ uses sildenafil, the same active ingredient found in Viagra®, to improve genital blood flow.
THE BIG “O” (OVERVIEW)
All participants had a main diagnosis of FSAD and may have also had concomitant sexual dysfunction diagnoses or symptoms including decreased desire, orgasmic dysfunction, and genital pain. Exploratory Phase 2b clinical study designed to evaluate Sildenafil Cream vs. placebo over 12 weeks of double-blinded dosing following both a non-drug and placebo run-in period: Compared Sildenafil Cream vs. placebo used in patients’ home setting. Co-primary endpoints: patient reported outcome (PRO) instruments measured improvement in localized genital sensations of arousal (Arousal-Sensation Domain of the Sexual Function Questionnaire) and reduction in FSAD related distress (Female Sexual Distress Scale).
Exploratory Phase 2b RESPOND Study, Completed in 2023
Secondary endpoint: measured change in the number of satisfactory sexual events Exploratory endpoints: Several efficacy endpoints measured and could be candidate endpoints in a Phase 3 study. Efficacy assessments were administered both on an electronic diary to be completed within 24 hours of a sexual event and via 28-day recall assessments. Sildenafil Cream-treated group showed meaningful improvement in the co‑primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire, although the endpoint did not achieve statistical significance.1 Post-hoc analyses showed that Sildenafil Cream met the Ph2b co-primary endpoint (SFQ28-arousal domain patient reported outcome (PRO)) and demonstrated clinically meaningful benefit in patients who have FSAD or FSAD with concomitant decreased desire. Secondary and exploratory endpoints saw these patients report meaningful improvement in arousal sensation, desire, orgasm, as well as stress, guilt, and embarrassment about the sexual dysfunction. Read more about the Phase 2b clinical study here. Applied topically, it’s designed for use as needed, to enhance the body’s natural arousal response without systemic effects, providing women with a new, evidence-based tool to take charge of their sexual health. “When Viagra was approved in 1998, it revolutionized sexual medicine for men. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “We believe DARE to PLAY™ represents a long overdue correction, giving women an option to reconnect with their own bodies, their pleasure, and their confidence, using science that finally recognizes their needs.” Existing products promoted for arousal lean heavily on marketing language, consumer reviews, and lifestyle branding without real evidence. DARE to PLAY™ is the first and only topical formulation of sildenafil developed specifically for women and backed by: Toxicology studies covering oral, anal, vaginal, and reproductive health; Multiple clinical trials in women, including a randomized placebo-controlled study with 200 women and their sexual partners; and Published, peer-reviewed research in medical journals such as The Green Journal, the official publication of the American College of Obstetrics and Gynecology (ACOG) and the Journal of Sexual Medicine, the official publication of the International Society for the Study of Women’s Sexual Health (ISSWSH). “As more women speak openly about their sexual health, the need for research-backed solutions has never been greater,” said Dr. Irwin Goldstein, Director of San Diego Sexual Medicine and a founder of ISSWSH. “Daré’s commitment to both clinical integrity and timely access ensures women who need it don’t have to wait to benefit from this innovation.” While continuing activities necessary to seek U.S. Food and Drug Administration (FDA) approval of its proprietary sildenafil cream formulation in the future, Daré Bioscience is making DARE to PLAY™ available as a Section 503B compounded product, manufactured in an outsourcing facility subject to FDA inspection and under current Good Manufacturing Practice (cGMP) regulations to ensure quality, strength and consistency. Compounded drug products are not FDA approved.
- The concept of Viagra cream emerged as a topical alternative.
- It is intended to bypass gastrointestinal absorption issues.
- Topical use may reduce the risk of cardiovascular side effects.
- Some formulations include additional botanicals for enhancement.
- It is part of a growing market for personal sexual wellness products.
- Regulations vary by country; some products are unapproved.
- Expect a warming or tingling sensation upon application.
- The cream should be stored in a cool, dry place.
- Discontinue use if skin redness or irritation occurs.
- Use as directed to prevent overdose or adverse reactions.
The FDA does not evaluate compounded drug products for safety, effectiveness, or quality.
“Better” means more orgasms!
Visit for more information on DARE to PLAY™, including how to access a prescription and to sign up for an alert on when it is available in your state. An estimated 20 million women in the United States experience challenges related to genital arousal, yet there are no FDA-approved therapeutics to address this need. The availability of DARE to PLAY™ through a cGMP 503B facility provides this large, underserved community of women access to a product uniquely supported by clinical evidence and scientific rigor. References to Section 503B, 503B, 503B compounding, 503B compounded product, and similar terms refer to Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) and the production and supply of compounded drugs by Section 503B-registered outsourcing facilities without patient-specific prescriptions in accordance with Section 503B. DARE to PLAY™ can now be prescribed for pre-order by licensed healthcare providers for prescription fulfillment in these states: CT, FL, IN, MO, NH, NJ, OR, PA, RI, and UT, and will ship within 45 days of order placement during the pre-order phase. DARE to PLAY™ prescriptions are being accepted through the DARE Health Hub, managed by Medvantx.
MeSH terms
During the trials, the Dare to Play cream increased libido as well as orgasms with no potential side effects compared to a placebo cream. It was also tested in oral sex situations. "Phase 2b trial included 200 premenopausal women experiencing symptoms of female sexual interest/arousal disorder, such as reduced genital sensation and frustration during intimacy," the company said. After 12 weeks, women who used the cream reported an increase in arousal as well as key areas of sexual function, including desire and orgasm. Johnson said the new cream represents a "long overdue correction" that allows women an option to reconnect with their own bodies, with science finally recognising their needs as well.
What is "scream cream"?
As for why a pill akin to those used by men was not developed, Johnson said a female pill would require a lot of sildenafil. She added that the option generic viagra sildenafil citrate 50 mg was "just not practical" as it would require much higher doses than what men generally need. Residents of Connecticut, Florida, Indiana, Missouri, New Hampshire, New Jersey, Oregon, Pennsylvania, Rhode Island and Utah can pre-order the cream already. Track Latest News Live on NDTV.com and get news updates from India and around the world Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY™ is expected to mark a breakthrough in women’s sexual health and represents important progress toward closing one of medicine’s most persistent gender gaps. DARE to PLAY™ will be available in other states throughout December and early 2026. Visit for more information on DARE to PLAY™, including how to access a prescription and to sign up for an alert on when it is available in your state. An estimated 20 million women in the United States experience challenges related to genital arousal, yet there are no FDA-approved therapeutics to address this need. The availability of DARE to PLAY™ through a cGMP 503B facility provides this large, underserved community of women access to a product uniquely supported by clinical evidence and scientific rigor. References to Section 503B, 503B, 503B compounding, 503B compounded product, and similar terms refer to Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) and the production and supply of compounded drugs by Section 503B-registered outsourcing facilities without patient-specific prescriptions in accordance with Section 503B.